| Management target | Revenue 17.0% H1'26 |
|---|
| Revenue growth | Q2/26 sales grew 7% YoY; H1/26 sales flat YoY. |
|---|---|
| Margins | Q2 PBT margins expanded from 24% to 27%. |
| Demand visibility | Strong diabetes demand; public sector accounts grew 70%. |
| Management confidence | High, citing modernized business model and strong diabetes momentum. |
Growth
Domestic sales hit ₹3,559 Mio (+8%). Total Q2 income reached ₹4,439 Mio (+7%). H1 2026 PBT margin stable at 29%.
Outlook
Diabetes unit grew 17% in H1'26. Focus on public sector expansion and AI-enabled commercial initiatives for sustainable growth.
Risks
Export business faced headwinds with -7% growth in 2025. H1 2026 total income slightly down -4% YoY.
Last quarter's promises, checked
Delivered
- Guided 2026 start on good note → delivered Q2 PBT +19% YoY (= BEAT)
- Guided insulin leadership/growth → delivered Q2 Insulins +14% (= BEAT)
- Guided OPEX efficiency → delivered Q2 other OPEX -9% (= BEAT)
Partly delivered
- Guided partnership stabilization → delivered Q2 partnership +2% (= PARTIAL)
Missed
- Guided domestic sales stabilization → delivered H1'26 sales flat YoY (= MISS)
Earnings Call Transcript filed with BSE, NSE: SANOFI. Summary written with AI assistance from the document.
Sanofi India Ltd: key numbers
- Share price
- ₹3,140.20
- Market cap
- ₹7,232 Cr
- Revenue (annual)
- ₹1,837 Cr
- Net profit (annual)
- ₹326.7 Cr
- P/E (TTM)
- 22.3×Sector 50.4×
- Promoter holding
- 60.40%+0.00% QoQ
- FII holding
- 5.69%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sanofi India Ltd
All →Sanofi India Legal & Regulatory
Sanofi India received a GST show cause notice alleging excess input tax credit claims. The total demand, including interest, is Rs. 23.74 Crore.
- Value
- ₹23.74 Cr
- From
- Commercial Tax Officer (Audit)-6.1, DGSTO-6, Bengaluru
Sanofi India Promoter Buying (Off-Market)
Sanofi Healthcare India acquired 3,500,000 equity shares (15.20%) of Sanofi India Limited via an inter-se promoter group transfer. The transaction was executed as a block deal.
- Promoter stake change
- +15.20%
Sanofi India Promoter Selling (Off-Market)
Hoechst GmbH transferred 3,500,000 shares of Sanofi India Limited to Sanofi Healthcare India Private Limited. This inter-se promoter group transfer represents a 15.20% stake.
Sanofi India Legal & Regulatory
Sanofi India disclosed that the State Tax Officer, Tiruvallur dropped a ₹1.07 Crore GST demand for FY 2022-23. The company confirmed no material financial or operational impact.
- Value
- ₹1.07 Cr
Sanofi India Promoter Buying (Off-Market)
Sanofi Healthcare India Private Limited, a promoter group entity, proposed an inter-se transfer of up to 3,500,000 shares from Hoechst GmbH. This transaction qualifies for open offer exemption.
- Promoter stake change
- +15.20%
Sanofi India Legal & Regulatory
The Supreme Court dismissed Sanofi India's petition to quash criminal proceedings. No penalty or operational restriction is imposed on the company at this stage.